达雷妥尤单抗治疗伴单克隆免疫球蛋白沉积的增生性肾小球肾炎一例  

Daratumumab in the treatment of proliferative glomerulonephritis with monoclonal immunoglobulin deposition:a case report

作　　者：刘秋菊 武东[2] 李慧敏 李小伟[1] LIU Qiuju;WU Dong;LI Huimin;LI Xiaowei(Department of Nephrology,Fuyang People's Hospital Affiliated to Anhui Medical University(Fuyang People's Hospital),AnhuiFuyang236000,China;Department of Clinical Pharmacy,Fuyang People's Hospital Affiliated to Anhui Medical University(Fuyang People's Hospital),AnhuiFuyang236000,China)

机构地区：[1]安徽医科大学附属阜阳人民医院(阜阳市人民医院)肾内科,安徽阜阳236000 [2]安徽医科大学附属阜阳人民医院(阜阳市人民医院)临床药学,安徽阜阳236000

出　　处：《临床药物治疗杂志》2024年第6期90-92,共3页Clinical Medication Journal

基　　金：安徽省重点研究与开发计划(2022e07020057)。

摘　　要：本文报道1例少见的伴有单克隆免疫球蛋白沉积的增生性肾小球肾炎。患者为49岁女性,临床表现为肾病综合征,肾活检病理提示伴单克隆免疫球蛋白(IgG3-κ)沉积的增生性肾小球肾炎。初治给予地塞米松+环磷酰胺+沙利度胺(CTDa)方案完全缓解,复发后予以硼替佐米+地塞米松(BD)方案治疗无效,且出现肾功能异常,调整为达雷妥尤单抗治疗后病情逐步缓解,肾功能恢复正常。This article presents report a rare case of proliferative glomerulonephritis with monoclonal immunoglobulin deposition.The patient was a 49-year-old female,the clinical manifestations were nephrotic syndrome,Renal biopsy pathology indicated proliferative glomerulonephritis with monoclonal immunoglobulin(IgG3-k)deposition.Dexamethasone+cyclophosphamide+thalidomide(CTDa)regimen provided complete remission at the initial treatment,but bortezomib+dexamethasone(BD)regimen was ineffective after recurrence,and renal function abnormalities occurred.After daratumumab therapy,the disease gradually remission and renal function returned to normal.

关 键 词：伴单克隆免疫球蛋白沉积的增生性肾小球肾炎 克隆定向治疗 硼替佐米 达雷妥尤单抗 

分 类 号：R969.3[医药卫生—药理学]